Aptar Pharma to Unveil Inhalation Drug Delivery Solutions at CPhI China 2018

May 24, 2018

Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting once again at CPhI China 2018, taking place from June 20-22 at the Shanghai New International Exhibition Center, Shanghai, China. At Booth No. N5F30, Aptar Pharma will be introducing new market innovations in inhalation drug delivery for the Chinese market, demonstrating the benefits of these exciting respiratory solutions designed to combat the effects of air pollution. They will also be showcasing their innovative Connected Device portfolio, which covers application fields such as Respiratory and Eye Care. Visitors will have the opportunity to discover these intuitive devices featuring ...

Read More

£2m backing from Archangels and SIB for UK drug delivery company BDD

Mar 20, 2018

  Funding will enable BDD to scale up GMP manufacture of revolutionary time controlled “pill within a pill”   Archangels, the Edinburgh-based business angel syndicate, the Scottish Investment Bank, the investment arm of Scotland’s enterprise agencies, and Bio-Images Drug Delivery Limited (BDD) announce the completion of a £2m funding round designed to enable BDD to scale its business, focusing on its unique OralogiKTM precision timed drug delivery system.   The OralogiK timed release technology enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after being swallowed by the patient. The performance ...

Read More

Designing Smart Integrated Drug Delivery Systems

Jan 4, 2018

Wearable drug delivery technology is a good example of how drug delivery technology providers continue to stay ahead of the curve. In his piece, Graham Reynolds of Global Biologics, West Pharmaceutical Services, looks into today’s advanced drug delivery systems, complex pieces of technology that can incorporate innovative and intuitive features that can make it easier for patients to self-administer critical medications. ...

Read More

Dance Biopharm and Phillips-Medisize Enter into Joint Development Agreement for Advanced Inhaled Insulin Delivery

Dec 4, 2017

Dance Biopharm Holdings Inc. (“Dance”), a privately-held biotechnology company focused on the development of Dance 501, a proprietary ‘soft-mist’ inhaled insulin product to treat diabetes, is pleased to announce that Dance has entered into a joint development agreement (JDA) with Phillips-Medisize, LLC, a subsidiary of Molex Electronic Technologies, LLC, a leader in electronic solutions, to develop a version of the Dance 501 device that has data connectivity for better management of diabetes treatment.   Phillips-Medisize brings world class software and hardware capabilities to implement Dance’s designs. Phillips-Medisize is currently involved in the design and manufacture of clinical devices for Dance ...

Read More

Phillips-Medisize and Molex at Compamed: One Team, Infinite Possibilities

Nov 13, 2017

Phillips-Medisize, a Molex company, will be exhibiting at K39 in hall 8a during COMPAMED 2017. COMPAMED takes place simultaneously with the Medica exhibition on November 13-16 in Düsseldorf. Come visit the booth to see the expanded and integrated Phillips-Medisize and Molex capabilities.   Phillips-Medisize, now with the added capabilities of Molex, provides medical OEMs with a one stop location for all its device strategy, design, and development and manufacturing services. Molex is one of the world’s largest interconnect producers, which designs and manufactures electronic, electrical and fiber optic systems and solutions. Molex’s global scale in electronics, and Phillips-Medisize’s device development ...

Read More